Madrigal pharmaceuticals reports fourth-quarter and full-year 2024 financial results and announces new two-year data demonstrating potential benefit of rezdiffra™ (resmetirom) in patients with compensated mash cirrhosis

Conshohocken, pa., feb. 26, 2025 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (mash), today reports fourth-quarter and year-end 2024 financial results and reviews business highlights.
MDGL Ratings Summary
MDGL Quant Ranking